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To identify gene loci associated with steroid-resistant
nephrotic syndrome (SRNS), we utilized homozygosity
mapping and exome sequencing in a consanguineous
pedigree with three affected siblings. High-density
genotyping identified three segments of homozygosity
spanning 33.6Mb on chromosomes 5, 10, and 15 containing
296 candidate genes. Exome sequencing identified two
homozygous missense variants within the chromosome 15
segment; an A159P substitution in myosin 1E (MYO1E),
encoding a podocyte cytoskeletal protein; and an E181K
substitution in nei endonuclease VIII-like 1 (NEIL1), encoding
a base-excision DNA repair enzyme. Both variants disrupt
highly conserved protein sequences and were absent in
public databases, 247 healthy controls, and 286 patients
with nephrotic syndrome. The MYO1E A159P variant is
noteworthy, as it is expected to impair ligand binding
and actin interaction in the MYO1E motor domain. The
predicted loss of function is consistent with the previous
demonstration that Myo1e inactivation produces nephrotic
syndrome in mice. Screening 71 additional patients with
SRNS, however, did not identify independent NEIL1 orMYO1E
mutations, suggesting larger sequencing efforts are needed
to uncover which mutation is responsible for the phenotype.
Our findings demonstrate the utility of exome sequencing
for rapidly identifying candidate genes for human SRNS.
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Nephrotic syndrome, characterized by the triad of heavy
proteinuria, hypoalbuminemia, and edema, can lead to
progressive damage of kidney glomeruli and end-stage renal
disease. Idiopathic nephrotic syndrome has a prevalence of
about 16/100,000 children.1,2 Although the majority of cases
(B80%) are steroid responsive and have no long-term renal
sequelae,3,4 steroid-resistant nephrotic syndrome (SRNS)
represents one of the most common causes of pediatric
end-stage renal disease. The typical histological lesion in
SRNS is focal segmental glomerulosclerosis (FSGS). Posi-
tional cloning studies have identified several genes mutated
in familial, non-syndromic forms of FSGS (NPHS1, NPHS2,
PLCE1, WT1, ACTN4, TRPC6, and INF2).5–10 All of these
genes encode proteins that are highly expressed in glomerular
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podocytes, the terminally differentiated visceral epithelial
cells whose highly organized actin–myosin cytoskeleton
provides structural support against pulsatile forces at the
glomerular filtration barrier. Podocytes also possess elaborate
foot processes that contribute to formation of the slit
diaphragm, the kidney filter. Although mutations in NPHS1
and NPHS2 are a common cause of childhood-onset,
autosomal recessive FSGS, mutations in other genes are very
rare. Thus, the genetic cause of the vast majority (480%) of
childhood-onset SRNS is still not known,11–15 indicating that
there are more, yet undiscovered, genes responsible for this
trait. The ability to identify SRNS by molecular diagnosis has
important clinical implications, as this would prevent
unnecessary administration of corticosteroids and direct
physicians to alternative therapies.
Identification of genes for nephrotic syndrome is compli-
cated by genetic heterogeneity and incomplete penetrance,
which limits availability of large pedigrees for traditional
positional cloning approaches. However, the recent advent of
exome capture, followed by massive parallel sequencing,
enables a rapid genome-wide search for rare pathogenic
mutations. This approach has successfully identified new
genes for rare monogenic diseases for which informative
pedigrees were not available and can also provide molecular
identification of Mendelian disorders when the clinical
diagnosis is uncertain.16–18 Here, we identified novel candi-
date genes for human autosomal recessive SRNS by genome-
wide homozygosity mapping, followed by exome sequencing.
RESULTS
Patients and families
We established a cohort of Caucasian pediatric patients with
nephrotic syndrome, comprising 234 steroid-resistant and 72
steroid-sensitive patients. This cohort includes 20 patients
from nine families (Figure 1a and Supplementary Figure S1
online). Mutations in NPHS2 and WT1 were excluded by
Sanger sequencing in the all nine families and in 219 sporadic
patients. In this cohort, one Italian pedigree (K3016,
Figure 1a) was ideally suited for genetic studies, as it
consisted of three siblings diagnosed with SRNS, born to a
consanguineous union between healthy parents, which is
strongly indicative of a simple autosomal recessive inheri-
tance (Figure 1a). All three affected individuals had kidney
biopsy–documented FSGS that was unresponsive to steroids,
with the age of onset ranging between 3 and 10 years. The
maximal expected logarithm of odds (LOD) score under a
simple autosomal recessive model was 2.7, indicating high power
for chromosomal localization of a new disease-causing gene.
Linkage analysis and homozygosity mapping localize a novel
gene to 33.6Mb
A genome-wide analysis of linkage with 393 microsatellite
markers (Marshfield Mammalian Genotyping Service,
performed in 2006) resulted in three suggestive signals on
chromosomes 5 (D5S1725; LOD score¼ 1.7), 10 (D10S1419;
LOD score¼ 1.4), and 15 (D15S643; LOD score¼ 2.4) under
an autosomal recessive model (Allegro 2.0 statistical pack-
age;18 disease gene frequency¼ 0.0001 and phenocopy
rate¼ 0.0001). Follow-up studies with more novel high-
density genotyping methods (Illumina 610-Quad chip;
Illumina, San Diego, CA) and haplotype analysis in the
three affected patients precisely localized the segments of
homozygosity, defining shared intervals spanning 2.98Mb on
chromosome 5, 0.26Mb on chromosome 10, and 30.32Mb
on chromosome 15 (Figure 1b). In addition, genome-wide
linkage analysis was repeated using a pruned set of 24,441
highly informative single-nucleotide polymorphisms (SNPs)
but did not identify additional shared homozygous segments.
Thus, altogether, high-density homozygosity mapping loca-
lized the causal variant(s) to three regions totaling 33.56Mb
of sequence (B1% of the human genome), containing
296 positional candidates. The chromosome 15 interval was
most likely to harbor the SRNS gene(s) as it spanned a
large segment of shared homozygosity and reached the
maximum expected LOD score of 2.7 between rs9788730
and rs3813573.
Exome sequencing identifies homozygous missense variants
in the MYO1E and NEIL1 genes
Given the large number of positional candidates, we
performed a comprehensive search for pathogenic mutations
by whole-exome sequencing in the index case (Figure 1a).
After capturing of 50Mb of human DNA sequence on an
Agilent array (Agilent, Santa Clara, CA), massive parallel
sequencing was conducted on a SOLiD 4 instrument
(Applied Biosystems, Carlsbad, CA). Nearly 95% of the
SureSelect regions were sequenced at an average of 65
depth, and 84% of the bases were covered at 10 depth or
more. Analysis restricted to the regions of homozygosity
demonstrated that B96.2% of the exons in these regions
were adequately captured or sequenced, indicating near-
complete coverage (the 135 exons on chromosome 15 and 3
exons on chromosome 5 that were not captured are listed in
Supplementary Table S1 online). This coverage is comparable
to published exome-sequencing experiments.16–18 We next
applied a Bayesian SNP calling to evaluate the previous
probability of the existence of a heterozygote or a non-
reference homozygote at the position.
A Bayesian SNP calling with an error correction algorithm
(SOLiD Accuracy Enhancer Tool (SAET), Carlsbad, CA) led
to the identification of 14,262 single-nucleotide variants in
the sample. After filtering these against the Single Nucleotide
Polymorphism Database and the 1000-Genomes Project, we
identified 665 unique variants. For quality control, we
examined SNP calls within the regions of homozygosity
defined by high-density genotyping and identified only four
heterozygous calls, indicating a low false-positive rate. There
were no homozygous truncating mutations or splice-site
variants across the genome. By restricting the analysis to the
shared regions of homozygosity on chromosomes 5, 10, and
15, we identified only four missense homozygous variants,
all located on chromosome 15: MYO1E, p.A159P; NEIL1,
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p.E181K; GOLGA6, p.R149Q; and TBD2B, p.V284L. Sanger
sequencing indicated that the GOLGA6 and TBD2B variants
were false positives, but the MYO1E p.A159P and NEIL1
p.E181K were present in homozygosity in all three affected
children and in heterozygous state in both parents (Figures 2
and 3). Analysis with PolyPhen-2 indicated that the MYO1E
p.A159P variant was most likely deleterious (score¼ 0.998)
and the NEIL1 p.E181K (score¼ 0.836) was possibly damag-
ing. However, MYO1E was a highly compelling candidate
because a recent study showed that Myo1e is expressed in
glomerular podocytes and its inactivation in mice results in
heavy proteinuria due to podocyte damage, recapitulating
human nephrotic syndrome,19 whereas inactivation of
murine Neil1 on two genetic backgrounds produces only
obesity and metabolic defects.20,21 Nevertheless, both variants
were absent in all public databases, 247 ethnically matched
healthy controls, and 286 independent pediatric patients with
steroid-resistant and -sensitive nephrotic syndrome. We also
performed Sanger sequencing in all 28 exons of MYO1E and
9 exons of NEIL1 in affected individuals in K3016 but found
no other coding variants.
We next sequenced all MYO1E and NEIL1 exons in the
index cases from 8 independent nephrotic syndrome families
(Supplementary Figure S1 online) and 63 sporadic cases with
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Figure 1 |Mapping a gene for steroid-resistant nephrotic syndrome to Chr. 15q21–26. (a) Pedigree structure of family K3016.
Individuals 10, 11, 12, and 13 were genotyped for linkage with 393 microsatellite markers across the genome (Marshfield Mammalian
Genotyping Service). The three affected siblings were genotyped with high-density single-nucleotide polymorphism arrays (Illumina
610-Quad) for linkage and homozygosity mapping. Individual K3016-11 was subjected to whole-exome sequencing. (b) Genome-wide
homozygosity plot. In red are indicated the three regions of significant homozygosity in which the haplotypes were identical by descent.
(c) University of California, Santa Cruz map of the 30.32-Mb segment of homozygosity on chromosome 15 containing 263 positional
candidates; MYO1E and NEIL1 are highlighted. (d) Graphical representation of the MYO1E and NEIL1 proteins, with the location of the
MYO1E A159P and NEIL1 E181K substitutions shown by arrows. The functional domains of each protein are also indicated. chr.,
chromosome; endonuclease, endonuclease VIII-like 1, DNA-binding domain; glycosylase, N-terminal domain of metazoan Nei-like
glycosylase 1; H2TH, formamidopyrimidine–DNA glycosylase helix 2 turn helix domain; IQ, IQ motif; myosin; myosin, motor domain; SH3, Src
homology-3 domain; TH1, C-terminal tail homology domain. ma¼maximum homozygosity scores (scale 0–1). Scores higher than 0.8 are
highlighted in red.
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ITC-F7-MY01E-6-R-6_R Fragment tase 123. Base 123 of 155
Figure 2 |Description of the MYO1E A159 substitution. (a) Chromatogram of the homozygous c.475 G4C variant resulting in the MYO1E
alanine-to-proline substitution at position 159 in K3016. The sequence variant is boxed in red. (b) Multiple protein sequence alignment
shows conservation of the alanine residue at position 159 in the myosin-1E protein, its homologs, and orthologs. (c) Ribbon diagram
of the crystal structure of the motor domain from MYOE from Dictyostelium discoideum (PDB ID 1LKX), the most highly related MYO1E
protein of known structure. The position of the proline mutation at A159 (A149 in D. discoideum) is colored in red; ADP is shown in blue,
Mg2þ in yellow, and a bound vanadate ion is shown in magenta. The mutation is positioned at the C-terminal end of helix 7, preceding a
loop that is disordered in the structure. This residue is positioned adjacent to the active site and is likely to interfere with ligand binding
or catalysis.32 Ala, alanine; Asn, asparagine phenylalanine; Gly, glycine; Lys, lysine; Phe, phenylalanine; Pro, proline; Thr, threonine.
Species
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Protein sequence (p.E181K)
Affected
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Unaffected
control
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a b
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Figure 3 |Description of the NEIL1 E181K substitution. (a) Chromatogram of the homozygous G4A variant resulting in the NEIL1 E181K
substitution in K3016. The sequence variant is boxed in red. (b) Multiple protein sequence alignment shows conservation of the glutamic
acid residue (E) at position 181 in the NEIL1 protein and in its homologs and orthologs. Ala, alanine; Arg, arginine; Glu, glutamic acid;
Ile, isoleucine; Leu, leucine; Lys, lysine; Tyr, tyrosine.
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onset of SRNS between 1 and 14 years, and in whom mutations
in NPHS2 andWT1 gene had been excluded.12,22 We identified
a few rare heterozygous variants (Supplementary Table S2
online), but none of the patients harbored two potentially
pathogenic variants for either MYO1E or NEIL1 genes. One
affected sib from family K3031 carried two potentially
deleterious variants in the MYO1E gene (D185G and
P1049H), but segregation analysis indicated that both variants
segregated in cis from the maternal side. Moreover, the affected
sib did not inherit this haplotype. Of note, we identified a
NEIL1 variant affecting a canonical splice donor site in
intron 1 (c.434þ 2T4C, identified in three cases), which is
predicted to result in premature termination signal; however,
this variant is present in public databases and in controls
(rs5745908, frequency¼ 0.013 among Europeans), indicating
that potentially disruptive mutations in NEIL1 may be
tolerated.
As inactivation of Myo1e gene causes nephrotic syndrome
in mice, we further analyzed the structure of MYO1E to
infer the potential functional consequence of the A159P
substitution. Position A159 is located within the myosin
motor domain, which mediates ligand binding and inter-
actions with actin, with alanine at this site conserved
among virtually all MYO1E orthologs and paralogs
(Figure 2b). The crystal structure of the highly conserved
MYO1E from Dictyostelium23 shows that the A149 residue,
which is equivalent to A159 in the human protein, is located
at the C terminus of helix 7, directly adjacent to the switch 1
domain involved in nucleotide binding (Figure 2c). Muta-
tions in this region in MYO1C and myosins II and V affect
nucleotide binding or ATP hydrolysis;24–30 thus, substitution
with the larger proline side chain at position 159 is highly
likely to interfere with ligand binding or catalysis. Taken
together, these data strongly indicate that the A159P
substitution is a loss of function mutation.
DISCUSSION
In this study, we used homozygosity mapping and exome
sequencing to identify MYO1E and NEIL1 as novel candidate
genes for human SRNS. The MYO1E and NEIL1 mutations
localized to the only large segment of homozygosity in a
consanguineous pedigree; these mutations were absent in
1066 independent chromosomes surveyed by Sanger sequenc-
ing; there were no other homozygous deleterious coding
mutations elsewhere in the genome, and both variants in
MYO1E and NEIL1 affect amino-acid residues that are highly
conserved across homologs and orthologs and affect func-
tional domains of the proteins. We screened all exons of
MYO1E and NEIL1 genes in 71 additional cases but did not
identify independent mutations in either gene, indicating
that MYO1E and/or NEIL1 mutations represent a relatively
rare cause of recessive SRNS in humans. These findings
motivate larger screening efforts to identify the contribution
of these genes to nephrotic syndrome.
MYO1E is a ubiquitously expressed member of class I
myosins, which are small, monomeric molecules that interact
directly with cell membranes via their C-terminal TH1
domain and with actin filaments via their N-terminal motor
domain, enabling control of plasma tension and mechanical
strain, dynamic gating of ion channels, microvillar vesicle
shedding, and endo/exocytosis.31,32 Cells with specialized
cytoskeletal organization, such as glomerular podocytes,
auditory hair cells, and enterocytes, are particularly enriched
in class I myosins, which enable them to regulate their
specialized membranes (for example, podocyte pedicels).
Heterozygous mutations in the MYO1A gene produce a
defect in hair cells, resulting in autosomal dominant hearing
loss in humans.33 Most relevant to the present work, a recent
study has shown thatMyo1e is highly expressed in glomerular
podocytes and Myo1e null mice develop selective podocyte
injury, with foot process effacement, severe proteinuria, and
progressive glomerulosclerosis,19 highlighting the importance
of the actin–myosin cytoskeletal integrity for maintenance of
the kidney filtration barrier.
NEIL1 gene encodes a ubiquitously expressed DNA
glycosylase involved in the base-excision repair of mito-
chondrial and nuclear DNA, which is important for protec-
tion against reactive oxygen species.34 Inactivation of Neil1 in
mice results in late-onset obesity, extensive in visceral fat
deposition, and biochemical features of metabolic syn-
drome.20,21 This is accompanied by mitochondrial DNA
depletion and impaired oxidative phosphorylation in hepato-
cytes.20,21 The renal phenotype of Neil1 null mice has not been
studied in detail, but available data indicate proximal tubule
vacuolization without detectable fat deposition.21 Interest-
ingly, we recently demonstrated that mutations in the DNA
repair gene Prkdc produce susceptibility to adriamycin
nephropathy in mice by impairing mitochondrial DNA
maintenance in podocytes.35 This observation provides a
potential mechanism that could link mutations in the NEIL1
gene to podocyte injury and SRNS.
Although the genetic evidence points to both NEIL1 and
MYO1E as the disease gene, and digenic disease cannot be
formally excluded in K3016, consideration of the literature
favors the MYO1E A159P substitution as the most likely
culprit mutation. Mutations in the nucleotide-binding
pocket in the myosin superfamily (for example, MYO1C,
MYOII, MYOV, and MYH7) are associated with many clinical
phenotypes, such as sensorineural hearing loss or cardiomyo-
pathy.24–30 For example, a recently described R156W muta-
tion in the MYO1C switch 1 domain corresponding to R163
in MYO1E, in close proximity to the A159P substitution
presently described, severely impairs function by reducing
duty ratio and force sensitivity, likely accounting for its
association hearing loss.27,30 Thus, it is likely that the MYO1E
substitution from an alanine to a proline at position 159, a
virtually invariant site near the ligand-binding site in the
myosin motor domain, similarly produces a loss of function
by impairing nucleotide binding and altering duty ratio.24–30
This predicted loss of function mechanism is consistent both
with the mouse knockout data and with previous findings,
demonstrating that mutations in other components of the
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actin–myosin network (for example, ACTN4 or INF2)
produce FSGS in humans.6,8
In summary, homozygosity mapping and exome sequen-
cing in a consanguineous kindred identified MYO1E and
NEIL1 as novel candidate genes for human autosomal
recessive SRNS, motivating comprehensive mutational
screening of both genes in larger cohorts to distinguish
whether mutations in one or both genes produce SRNS.
These results highlight the power of next-generation sequenc-
ing in defining candidate genes for Mendelian disorders in
the setting of high genetic heterogeneity, providing a strong
rationale for more systematic whole-exome sequencing in
human SRNS.
MATERIALS AND METHODS
Patients and families
Patient recruitment was performed at different research units in Italy
(Genova, Brescia, Parma, and Foggia) and New York (Columbia
University). Inclusion criteria for enrollment were: nephrotic range
proteinuria; age of onset o18 years of age; histological findings of
FSGS, diffuse mesangial sclerosis; or minimal change nephropathy.
Family K3016 was recruited in 2002. We collected peripheral blood
samples for DNA isolation from all affected patients and available
family members. The Institutional Review Board for Columbia
University, and local ethic review committees in Genova, Brescia,
Naples, Parma, and Foggia approved our protocol.
DNA isolation and genotyping
Genomic DNA was purified from peripheral blood cells using
standard procedures. The genome-wide microsatellite scan was
performed with 393 microsatellites (intermarker distance B10 cm)
genotyped across the genome in the three affected individuals from
K3016 and in one parent in 2006 (Marshfield Mammalian
Genotyping Service). In 2009, to maximize inheritance information
across the genome and to identify areas of shared homozygosity,
we also genotyped the three affected individuals using the Illumina
610-Quad gene-chip array, which features over 620,000 markers
across the genome. DNA processing and gene-chip hybridization
were performed as recommended by the manufacturer. Clustering,
normalization, and genotype calls were performed using the dedi-
cated GenomeStudio 2010.3 Genotyping Module (Illumina).
Exclusion of NPHS2 and WT1 mutations
Mutational screening of NPHS2 and WT1 was performed by
bidirectional Sanger sequencing of exons and flanking introns
in nine families with autosomal recessive nephrotic syndrome
(including K3016) and 219 sporadic patients with steroid-
resistant or steroid-dependent nephrotic syndrome, as previously
described.12,22 Mutations in these genes were excluded in pedigree
K3016 in 2003. An additional 67 sporadic patients were either
steroid sensitive or recently recruited and not yet tested for
mutations in known genes.
Linkage analysis and homozygosity mapping
Analysis of linkage was performed using the 393 microsatellite
markers (Marshfield Mammalian Genotyping Service) and a pruned
dataset of 24,441 SNPs, obtained by removing SNPs with minor
allele frequency o0.01, Hardy–Weinberg equilibrium, P-value
o5 107, and r240.05, on a training set of 2716 Italian
individuals genotyped with the Illumina 1M-Duo chips. Analyses
were conducted using the PLINK software.36 Parametric linkage
analysis was conducted under an autosomal recessive mode of
inheritance, with disease gene frequency¼ 0.0001 and phenocopy
rate¼ 0.0001, using Allegro 2.0 statistical package.18 Homozygosity
mapping was conducted on the three affected patients from K3016
genotyped on the Illumina 610-Quad using Homozygosity Mapper
(http://www.homozygositymapper.org/).
Whole-exome capture followed by massive parallel
sequencing
Next-generation sequencing was performed in 2010 on a SOLiD 4
System (Applied Biosystems) according to the manufacturer’s
instruction. Briefly, Agilent SureSelect 50Mb Human All Exon
kit for SOLiD was used for the sequence capture. This kit
allows to selectively capture 50Mb of genomic DNA, including
over 180,000 exons, 700 human microRNAs from the Sanger v13
database, and over 300 additional human non-coding RNAs, such
as snoRNAs and scaRNAs, representing 1.22% of human genomic
regions.
Fragment libraries were prepared using 3mg of genomic DNA as
starting material. Upon shearing, the libraries were prepared using the
Beckman Coulter SPRIworks automated library preparation kit
(Brea, CA) with SureSelect AB adaptors. A total of 500 ng of prepared
library was hybridized with the baits for 48h, washed, and eluted using
the protocol provided by Agilent Technologies. The resulting captured
DNA was amplified using Platinum PCR SuperMix High Fidelity
amplification kit (Invitrogen, Carlsbad, CA). Enrichment in the
targeted regions was determined before sequencing by real-time PCR
quantification of several genomic loci within the capture design. After
quantification by real-time PCR, the amplified captured libraries were
subjected to emulsion PCR using the EZ bead system (Applied
Biosystems) and sequenced using the SOLiD 4 instrument and paired-
end protocols. To minimize the false-positive SNP calls, we applied an
error correction algorithm before SNP calling (SAET). We applied a
Bayesian SNP calling to evaluate the previous probability of the
existence of a heterozygote or a non-reference homozygote at the
position. The data were then filtered against the Single Nucleotide
Polymorphism Database and the 1000-Genome Project to identify
novel variants in the sequenced sample.
Next-generation sequencing data analysis
High-quality sequencing reads were aligned to the human genome
reference sequence from University of California, Santa Cruz
assembly hg18. For each genome alignment, single-nucleotide
discrepancies and small insertion/deletions in comparison with the
reference genome were searched. The variations were regarded as
reliable SNPs if they achieved minimum quality score. Bioscope 1.2
with progressive mapping option was used to align the pair-end
library reads (50þ 35 bp) to human genome hg18. This mapping
algorithm chooses the alignment with the highest score and the
shortest matches if multiple possibilities have the same score. Bayesian
SNP calling was used, which evaluates the posterior probability of the
existence of a heterozygote or a non-reference homozygote at the
position. On the basis of the probability of SNP evidence being a
miscolor call, position error, or probe error, the Bayesian algorithm
uses the previous probability of the position being a heterozygote and
the probability of observation being correct. The probabilities are
calculated from the quality values of color calls, the frequencies of
dicolor read mismatches as a function of positions in a read, or from
the frequencies of mismatches as the function of 6-mer probe prefix.
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To minimize the false-positive SNP calls, we performed the error
correction algorithm (SAET) before SNP calling.
Validation and search for independent mutations via
traditional Sanger sequencing
All homozygous variants that were identified by exome sequencing
and that were included into the pedigree K3016 regions of
homozygosity were validated by traditional Sanger sequencing. To
identify independent mutations, we conducted Sanger sequencing of
all exons and exon–intron boundaries of the MYO1E (28 exons) and
NEIL1 (nine exons) in index cases from an additional eight
independent families with autosomal recessive nephrotic syndrome
and 63 Italian patients with sporadic SRNS with disease onset
between 2 and 14 years of age (comparable to family K3016) and no
mutations in NPHS2 or WT1. In addition, exon 6 of MYO1E and
exon 2 of NEIL1 were sequenced in an additional 211 patients with
SRNS (including 192 patients negative for mutations in NPHS2 and
WT1 gene) and in 67 patients with steroid-sensitive nephrotic
syndrome. The pathogenic role of each missense variant was
assessed by publicly available prediction programs (PolyPhen-2:
http://genetics.bwh.harvard.edu/pph2/) and by protein modeling
using the highly related myosin protein from Dictyostelium
discoideum (PDB ID 1LKX) in the Protein Data Bank (http://
www.rcsb.org/pdb/). The frequencies of all rare variants were further
determined by direct sequencing of 247 ethnically and geographi-
cally matched controls.
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